TITLE

Boston Scientific's Stroke Device Shows Mixed Results

PUB. DATE
March 2013
SOURCE
MondayMorning;3/18/2013, Vol. 21 Issue 10, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses the safety issue related to heart device for preventing strokes by the company Boston Scientific Corp. It is mentioned that test for effectiveness and safety of the device is required by the U.S. Food and Drug Administration. It is also mentioned that the device led to strokes in some patients while implanting it.
ACCESSION #
86435102

 

Related Articles

  • Boston Sci's Precision lead splitters approved.  // Medical Device Daily;6/25/2010, Vol. 14 Issue 122, p8 

    The article relates the announcement by Boston Scientific in June 2010 about U.S. Food and Drug Administration (FDA) approval and introduction of two spinal cord stimulation (SCS) lead splitters for use with Precision Plus spinal cord stimulator system.

  • Noted….  // Medical Design Technology;Jan2007, Vol. 11 Issue 1, p9 

    The article offers news briefs related to use of medical devices in the U.S. The Boston Scientific Corp. recalls 51 units of its Mach 1 guide catheters. The Abiomed Inc. announces its new minimally invasive intra-aortic balloon designed to enhance blood flow to the heart and other organs for...

  • FDA clearance for oxygen level brain monitor won by OrNim.  // Biomedical Business & Technology;May2008, Vol. 31 Issue 5, p18 

    The article presents updates on product approvals received by several companies. OrNim Medical has received a clearance from the U.S. Food and Drug Administration (FDA) for its CerOx device. Boston Scientific said the Japanese Ministry of Health, Labor and Welfare has approved its Acuity...

  • FDA clears plant restrictions at Boston Scientific's St. Paul facility.  // Cardiovascular Device Update;May2007, Vol. 13 Issue 5, p16 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to lift restrictions from a warning letter it issued to Boston Scientific after the re-inspection of one of its plants that makes cardiac rhythm management devices in Saint Paul, Minnesota. FDA found that the...

  • Boston Scientific Rolls Out Updated Version of its SpyGlass System.  // Medical Product Outsourcing;Mar2015, Vol. 13 Issue 2, p24 

    The article medical technology news briefs in the U.S. as of March 2015. Topics discussed are the 510(k) clearance given by the U.S. Food and Drug Administration (FDA) to the SpyGlass DS Direct Visualization System for use in cholangioscopy and pancreatoscopy procedures manufactured by Boston...

  • FDA approves Boston Sci for expanded indication for CRT-D. McCARTY, MARK // Medical Device Daily;9/20/2010, Vol. 14 Issue 182, p1 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of Boston Scientific's (BSX) application for extended indications for cardiac resynchronization therapy/defibrillation (CRT-D) in September 2010. It traces the process of development that BSX has undergone...

  • Boston Sci launches Interlock -- 35 coil in U.S. and Europe.  // Medical Device Daily;7/5/2011, Vol. 15 Issue 122, p1 

    The article announces the U.S. and European launch by Boston Scientific of its Interlock-35 Fibered IDC occlusion system. The product received the U.S. Food and Drug Administration (FDA) clearance and CE mark approval in early 2011. Particular focus is given to the design features of the...

  • Restrictions removed, Boston Sci wins FDA approval of new lead.  // Medical Device Daily;4/18/2007, Vol. 11 Issue 74, p10 

    The article reports that the U.S. Food and Drugs Administration approved the Acuity Steerable left ventricular lead of Boston Scientific after the company lifted warning restrictions. The new lead is used with cardiac resynchronization therapy defibrillators and pacemakers in treating heart...

  • Boston Scientific Settles Warning Letter Issues.  // Medical Product Outsourcing;Sep2010, Vol. 8 Issue 7, p15 

    The article reports on the Boston Scientific Corp.'s resolution of the regulatory issues stated in the warning letter of the U.S. Food and Drug Administration (FDA). It discusses the issues in the warning letter that cited the deficiencies at several facilities of the company throughout the U.S....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics